Estrella Immunopharma, Inc. (ESLA) Key Metrics
ESLA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $18.7M
- Enterprise value
- $20.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.1 10-yr median 51.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.93
ESLA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsESLA valuation Price multiples at each fiscal year-end price.
ESLA returns How much profit the business earns on the capital it uses.
ESLA per-share figures Results divided by the shares outstanding at year-end.
ESLA financial health Debt, liquidity and how easily interest is covered.
ESLA valuation history
ESLA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ESLA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ESLA cash returned to shareholders
ESLA price vs earnings per share
ESLA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $57.4M | $44.0M | $40.3M | $362.2M | $348.8M | — |
| Enterprise value | $56.1M | $43.1M | $36.1M | $362.7M | $344.8M | — |
| Price / book | — | 306.2 | 9.4 | 51.2 | — | — |
| Earnings yield | −22.7% | −20.1% | −18.2% | −3.1% | −0.5% | — |
| Free cash flow yield | −3.1% | −7.1% | −39.9% | −0.3% | −0.4% | — |
| Shareholder yield (dividends + buybacks) | 0.1% | 0.5% | 0.9% | 10.0% | 0.0% | — |
| Share price at fiscal year-end | $1.56 | $1.20 | $1.11 | $10.29 | $9.91 | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.35 | −$0.24 | −$0.20 | −$0.32 | −$0.05 | −$0.02 |
| Operating cash flow per share | −$0.05 | −$0.08 | −$0.44 | −$0.03 | −$0.04 | −$0.02 |
| Free cash flow per share | −$0.05 | −$0.08 | −$0.44 | −$0.03 | −$0.04 | −$0.02 |
| Cash per share | $0.04 | $0.02 | $0.11 | $0.00 | $0.12 | — |
| Book value per share | −$0.28 | $0.00 | $0.12 | $0.20 | −$0.03 | $0.00 |
| Tangible book value per share | −$0.28 | $0.00 | $0.12 | $0.20 | −$0.03 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | — | $0.01 | — | — |
| Shares outstanding | 36.8M | 36.7M | 36.3M | 35.2M | 35.2M | 35.2M |
| Change in shares outstanding | +0.4% | +1.1% | +3.1% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | — | −400.6% | −128.9% | −368.6% | — | — |
| Return on invested capital (ROIC) | — | — | −151.2% | −731.6% | — | — |
| Return on assets (ROA) | −413.5% | −233.0% | −101.3% | −149.1% | −68.5% | — |
| Return on tangible assets | −411.2% | −281.7% | −164.2% | −111.3% | −34.2% | — |
| Financial health | ||||||
| Total debt | — | — | — | $498,600 | — | — |
| Cash & short-term investments | $1.4M | $916,916 | $4.2M | $40,802 | $4.1M | — |
| Net debt | −$1.4M | −$916,916 | −$4.2M | $457,798 | −$4.1M | — |
| Debt / equity | — | — | — | 0.07 | — | — |
| Debt / assets | — | — | — | 0.05 | — | — |
| Current ratio | 0.12 | 0.55 | 24.65 | 0.05 | 5.20 | — |
| Quick ratio | 0.12 | 0.55 | 24.65 | 0.05 | 5.20 | — |
| Working capital | −$11.9M | −$1.4M | $4.3M | −$1.0M | $4.0M | $0 |
| Invested capital | −$11.8M | −$773,185 | $108,060 | $7.5M | −$5.1M | $0 |
| Tangible asset value | −$10.4M | $143,731 | $4.3M | $7.1M | −$1.0M | $0 |
| Net current asset value | −$11.9M | −$1.4M | $4.3M | −$2.9M | −$1.0M | $0 |
| Graham net-net per share | −$0.33 | −$0.05 | $0.11 | −$0.08 | −$0.05 | $0.00 |
| Capital allocation | ||||||
| Share buybacks (net) | $29,462 | $214,477 | $354,440 | $36.1M | $25,000 | — |
| Capex / depreciation | — | — | — | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||
| Receivables turnover | — | 0.00 | — | 0.00 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average receivables | — | $288,761 | — | $273,066 | — | — |
| Average payables | $315,928 | $38,538 | $23,440 | $496,233 | $472,794 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Computed from ESLA's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ESLA valuation and financial ratios
It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks. The share count rose 4.6% from 35.2M to 36.8M over 5 years.
See the ESLA income statement, the ESLA chart for price history, or the ESLA stock overview for the latest quote and news.
ESLA key metrics FAQ
Does Estrella Immunopharma buy back its shares?
Yes. Estrella Immunopharma spent $0.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.4% over the year, to 36.8M..
What is Estrella Immunopharma's free cash flow yield?
Estrella Immunopharma generated -$1.8 million of free cash flow in fiscal 2025, a free cash flow yield of −3.1% on its market value at year-end ($57.4 million).
What is Estrella Immunopharma's current ratio?
Estrella Immunopharma's current ratio was 0.12 at the end of fiscal 2025: current assets were 0.12 times current liabilities.